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Many human diseases arise through dysregulation of genes that control key cell fate 
pathways. Transcription factors (TFs) are major cell fate regulators frequently involved 
in cancer, particularly in leukemia. The GFI1B gene, coding a TF, was identified by 
sequence homology with the oncogene growth factor independence 1 (GFI1). Both GFI1 
and GFI1B have six C-terminal C2H2 zinc fingers and an N-terminal SNAG (SNAIL/GFI1) 
transcriptional repression domain. Gfi1 is essential for neutrophil differentiation in mice. 
In humans, GFI1 mutations are associated with severe congenital neutropenia. Gfi1 is 
also required for B and T lymphopoiesis. However, knockout mice have demonstrated 
that Gfi1b is required for development of both erythroid and megakaryocytic lineages. 
Consistent with this, human mutations of GFI1B produce bleeding disorders with low 
platelet count and abnormal function. Loss of Gfi1b in adult mice increases the absolute 
numbers of hematopoietic stem cells (HSCs) that are less quiescent than wild-type 
HSCs. In keeping with this key role in cell fate, GFI1B is emerging as a gene involved in 
cancer, which also includes solid tumors. In fact, abnormal activation of GFI1B and GFI1 
has been related to human medulloblastoma and is also likely to be relevant in blood 
malignancies. Several pieces of evidence supporting this statement will be detailed in 
this mini review.
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Hematopoiesis, the process of formation of blood cellular components, provides an ideal model for 
cell differentiation of particular interest, as maturation block plays a crucial role in the pathogenesis of 
blood malignancies. It is regulated by transcription factors (TFs) that control gene expression, bind-
ing to specific DNA sequences and recruiting protein complexes that modify chromatin. Therefore, 
TFs are essential to establish a homeostatic balance, and they also play an essential role in disease.
Growth factor independence 1 (GFI1) and its homolog GFI1B are lineage-specific TFs required 
for hematopoiesis. GFI1 was discovered as a proviral integration site that confers IL-2-independency 
in T-cells infected by Moloney murine leukemia virus and was mapped to chromosome 1 of the 
human genome (1p22) (1, 2) (Figure 1A). The GFI1 paralog—GFI1B—was identified by its sequence 
homology with GFI1 and mapped to chromosome 9 of the human genome (9q34.13) (3, 4).
GFi1 AnD GFi1B STRUCTURe AnD FUnCTiOn
Growth factor independence 1 and GFI1B share two domains with over 95% identity. The conserved 
N-terminal SNAG domain contains 20 amino acids, which recruit proteins that modify histones 
(4–6). This domain has a nuclear localization motif and plays an important role in transcriptional 
repression through the binding of cofactors lysine-specific histone demethylase 1A (KDM1A, also 
FiGURe 1 | Schematic representation of human growth factor independence 1 (GFI1) and GFI1B genes and corresponding protein domains:  
(A) diagram of human GFI1 locus and protein. On top, the black horizontal line represents the DNA sequence, red boxes on the sequence are coding GFI1 
exons (Ex), and white boxes indicate UTRs. Underneath, GFI1 protein domains are indicated (green crescent represents the SNAG domain, and orange boxes are 
zinc fingers), the numbers over the blue rule indicate the amino acid positions; (B) GFI1B locus and long protein isoforms are depicted as in panel (A). The zigzag 
lines joining the Ex represent the splicing. Known mutations are shown on the protein and briefly described [acute myeloid leukemia (AML)]. (C) Short GFI1B splice 
variant and protein represented as in panels (A,B).
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known as LSD1) and RCOR1/2 (COREST) (6–8). However, the 
SNAG domain is not required for GFI1 interaction with corepres-
sors euchromatic histone lysine methyltransferase 2 (EHMT2, 
G9A) and histone deacetylase HDAC 1 (9), suggesting that dif-
ferent portions of these proteins cooperate in gene repression, 
possibly with different peculiarities in each TF.
The C-terminal domain is formed by a highly conserved 
region with six C2H2 zinc fingers. Fingers 1, 2, and 6 are required 
for protein interaction, whereas fingers 3–5 are necessary to 
bind DNA at an AATC containing motif [TAAATCAC(T/A)
GC(A/T)] (10, 11).
Between both domains, there is a less-characterized region 
that completely differs in both proteins, the function of which is 
still unknown.
This region is responsible for the size difference in both pro-
teins: GFI1 has 422 amino acids (55 kDa), while GFI1B consists of 
330 amino acids (37 kDa, CCDS6957) (Figure 1B). There is also a 
short 284 amino acid GFI1B isoform (CCDS48049) (Figure 1C) 
that lacks the first two zinc-finger domains as a result of an alter-
native splicing, skipping exon 5 (ENST00000372123.4).
Although GFI1 and GFI1B are similar in structure and share 
functional mechanisms, they show distinct cell expression 
patterns. Both GFI1 and GFI1B have an important role in the 
endothelial cell to hematopoiesis transition, the process by which 
endothelial cells become blood cells during the third wave of 
blood development. This generates the first hematopoietic stem 
cells (HSCs) in the intraembryonic aorta–gonad–mesonephros 
region, silencing the endothelial program. Interestingly, the 
expression pattern of both genes is different: Gfi1 is specifically 
expressed within the dorsal aorta in endothelial cells and cells 
within emerging intra-aortic hematopoietic clusters, whereas 
Gfi1b expression is more associated with the fully formed intra-
aortic hematopoietic clusters (12). This suggests that although 
both proteins can apparently compensate for the loss of one gene 
by the other, they play unique differential roles in vivo.
Knockout (KO) mice have shown that Gfi1 is essential for 
neutrophil differentiation (13, 14); consistently, in humans, 
severe congenital neutropenia is associated with GFI1 mutations 
(15). Gfi1 is also required for B and T lymphopoiesis (Figure 2). 
Besides being expressed in the hematopoietic system, Gfi1 is also 
expressed in precursors of sensory neurons, the retina, specific 
lung cells, and in the central nervous system (16).
GFI1B is expressed in HSCs, common myeloid and mega-
karyocyte/erythroid progenitors, and erythroid and megakaryo-
cytic lineages. Moderate levels of expression are also found in 
immature B-cells, a subset of early T-cell precursors (17, 18) and 
peripheral blood granulocytes and monocytes. GFI1B is very low 
or absent in lymphoid-primed multipotent, common lymphoid, 
early thymocyte, and granulocyte–monocyte progenitors (19) 
(Figure 2).
GFI1B role in erythropoiesis is crucial for expansion and 
differentiation of erythroid progenitors. Gfi1b deficiency in mice 
results in embryonic lethality by day E15 (20). Gfi1b null embryos 
display a delay maturation of erythrocytes and die because of the 
lack of enucleated erythrocytes. Gfi1b KO mice also fail to develop 
megakaryocytes but have arrested erythroid and megakaryocytic 
precursors in the fetal liver. Loss of Gfi1b in adult mice increases 
the absolute numbers of HSCs that are less quiescent than wild-
type ones (21), ablates erythroid development at an early progeni-
tor stage, and blocks terminal megakaryocytic differentiation in 
the polyploid promegakaryocytes that fail to produce platelets 
(22). Lineage-specific KOs have shown that the role of Gfi1b in 
megakaryocyte polyploidization and motility can be achieved 
by inhibiting p21 activated kinases, and the effect on proplatelet 
formation, by controlling α-tubulin expression, which is highly 
decreased in the KO cells (23).
The short GFI1B variant seems important for erythroid 
development and to show a stronger repressor activity than the 
long one (24). Instead, hyperexpression and knockdown experi-
ments in human primary cells have shown that the long GFI1B 
is required for megakaryopoiesis, but not the short form (25), 
which may have an inhibitory effect on platelet production (26) 
(Figure 2).
It has also been observed that the absence of Gfi1 and Gfi1b 
expression produces a severe block in B-cell development. On 
the contrary, in  vitro overexpression of Gfi1b inhibits myeloid 
differentiation of a cultured myelomonocytic cell line (4).
However, GFI1 and GFI1B are not just different in terms of 
cell specificity, as demonstrated by sequence interchange (27). 
Consistent with this, Gfi1 hyperexpression can rescue erythroid 
and early megakaryocytic differentiation from adult mouse 
Gfi1b KO, but terminal megakaryocyte maturation defect can-
not be compensated by Gfi1 or Gfi1b hybrid containing the Gfi1 
N-terminal portion (22). These differences are more patent in the 
inner ear than in hematopoietic cells (27).
GFi1B neTwORKS
At the DNA level, GFI1B represses the following: CDKN1A 
(4); proto-oncogenes myc, myb (28); GFI1 (29) and Meis1 (7); 
tumor suppressor genes Socs1 and Socs2 (30); the antiapoptotic 
gene BCL2L1 (BCXL) (31); TGFβR3 (32); GFI1B itself (29); T 
lymphopoiesis regulator GATA3 (33); hematopoietic master 
regulators SPI1 (PU.1) (34); and GATA2 (19), among other genes 
such as MGEA5, CSDE1, GABPB2, and ITSN1 (24). Recent 
insights into the role of Gfi1b in megakaryopoiesis have revealed 
new targets repressed by this TF. These include the regulator of 
G-protein signaling 18, which is differentially regulated in eryth-
roid and megakaryocytic cells, with low expression in the former 
and high expression in the latter (35). It also represses Fermt3 
(Kindlin3) required for integrin-mediated platelet adhesion and 
Talin1, involved in integrin–cytoskeleton connections (36). This 
is consistent with observations in the megakaryocyte-specific KO 
model, indicating the importance of Gfi1b control of cytoskeletal 
and integrin-binding proteins (23).
Besides its repressive function, GFI1B may directly or indi-
rectly activate gene expression; for example, MEF2C upregulation 
in T-cells by GFI1B binding to this gene promoter and MLLT3, 
whose expression correlates with GFI1B hyperexpression or 
functional block (34).
At the protein level, GFI1B interacts with hematopoietic TFs 
such as SCL, E2A, and GATA1 and with corepressors RUNX1T1 
(ETO), CBFA2T3 (ETO2) (37–39), SUV39H1 (40), KDM1A, 
RCOR1/2, HDACs, and EHMT2.
FiGURe 2 | Differential expression of growth factor independence 1 (GFI1) and GFI1B during hematopoiesis. Upward pointing black arrows indicate high 
expression, and downward pointing black arrows represent low expression. The long and short GFI1B isoforms are represented as in Figure 1. The blue arrows 
indicate a positive impact on cell differentiation, and the red line reflects an inhibitory effect. Several evidences point to the role of GFI1B mutations and increase 
expression of the short variant in leukemogenesis (dashed arrow). HSC, hematopoietic stem cell; MPP, multipotent progenitor; CMP, common myeloid progenitor; 
MEP, megakaryocyte and erythroid progenitor; GMP, granulocyte and monocyte progenitor; CLP, common lymphoid progenitor.
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These findings suggest that GFI1B plays a major role in hemat-
opoiesis. Its importance is also reflected by the tight control of 
its expression. We have identified several evolutionary conserved 
non-coding elements (CNEs) containing multiple erythroid/meg-
akaryocytic-specific TF-binding sequences, three downstream 
and one in the first intron (37). Chromatin immunoprecipitation 
studies in human and mouse demonstrated that GATA1, TAL1 
(SCL), NFE2, LDB1, LMO2, SPI1 (PU.1), MYB (37), TCF3 (E2A) 
(33, 37), and GATA2 (19, 41) are bound to the promoter and/or 
these distant regulatory elements in vivo in human and mouse. 
This is particularly significant at CNEs +1 and +3, corresponding 
to mouse DNase1 hypersensitivity sites +13 and +17 (coordinates 
in relation to the ATG start codon in Kb) (37). These downstream 
elements have been validated as hematopoietic enhancers in 
transgenic mouse assays (19). Interestingly, these sites also bind 
repressors and corepressors GFI1B, CBFA2T3 (ETO2), RCOR1 
(COREST), and KDM1A and could behave as negative regulatory 
elements depending on the GFI1B levels (37).
PLATeLeT DeFiCienCieS AnD BLeeDinG 
DiSORDeRS
Consistent with the Gfi1b KO effect on megakaryopoiesis 
(20, 22, 23), different mutations in GFI1B are involved in platelet-
related bleeding disorders (42).
A mutation described by Stevenson et al. (43), which consists 
of a single-nucleotide insertion in GFI1B exon 7 (c.880_881insC) 
that produces a frameshift and protein premature termination 
(His294fsTer307, g.135866324dupC in GRCh37/hg19 assembly) 
(Figure 1B: 7), disrupts the integrity of the fifth zinc finger and 
eliminates the coding sequence for the sixth zinc-finger domain. 
The mutated protein cannot bind to DNA and loses its repressor 
activity on target genes. This mutation was described in patients 
with an inherited dominant bleeding disorder with moderate 
macrothrombocytopenia and anisopoikilocytosis. Platelets of 
affected patients had substantial reductions in the α-granule 
components, P-selectin, and Fg, and somewhat less glycoproteins 
GPIba and GPIIIa.
Next, Monteferrario et  al. (44) detected a nonsense heredi-
tary mutation (c.859C>T) in the amino acid 287 (Gln287Ter, 
g.135866303C>T in GRCh37/hg19) (Figure 1B: 6) in a family 
with similar clinical features. This mutation also produces a stop 
codon and a truncated protein that lacks 44 amino acids at the 
carboxyl terminus. Normal levels of mRNA are expressed in the 
mutant allele, but the truncated protein is inactive as a repressor.
The condition produced by both mutations was considered a 
type of gray platelet syndrome, as platelets look gray under optical 
microscopy owing to their lack of alpha granules. However, the 
variable and, in general, less severe α-granule deficiency and the 
red cell phenotype differ from the classic gray platelet syndrome 
(45). This has led to classify these conditions as bleeding disorder 
platelet-type 17 (OMIM #187900).
Recently, another GFI1B mutation Gly272fsTer274 (c.814+ 
1G>C, g.135865294G>C, GRCh37/hg19) (Figure  1B: 5), 
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generating a truncated protein, has been associated with congeni-
tal macrothrombocytopenia linked to α-granule deficiency. This 
mutation affects 58 amino acids of the C-terminal, which results 
in complete deletion of zinc finger 5. Platelets in these patients 
present an increased level of CD34 expression and decreased 
levels of thrombospondin-1 (46).
GFI1B mutations have also been found in two patients from 
unrelated families with a combined alpha–delta storage pool 
deficiency, with reduction of α and dense (δ) granules. Both 
cases had thrombocytopenia. One of them had also anemia and 
a granulocytic left shift that corrected itself spontaneously in a 
few months. One patient also had urogenital and heart abnor-
malities and developed seizures. The other patient had persistent 
ductus arteriosus. A whole-exon sequencing of the first patient 
demonstrated a de novo heterozygous GFI1B nonsense muta-
tion—Lys265Ter (c.793A>T, g. 135865273A>T in GRCh37/
hg19) (Figure 1B: 4). Targeted GFI1B sequencing in the second 
case revealed a homozygous mutation at this gene—Leu308Pro 
(c.923T>C, rs775963992, g.135866367T>C in GRCh37/hg19) 
(Figure 1B: 8). These mutations too were located at zinc-finger 
domains 4 and 6, respectively. It is still unclear if the non-hemato-
logical congenital abnormalities observed in these patients were 
related to the GFI1B mutations (47).
A GFI1B sequence study of 529 patients with atypical platelet 
phenotypes also allowed for the identification of seven cases with 
non-synonymous single-nucleotide polymorphism affecting this 
locus, which was absent in 11,216 unaffected individuals. Four of 
them were located at zinc fingers 1 and 2, highlighting the impor-
tance of these domains. One of these variants was a homozygous 
Cys168Phe (c.503G>T, rs527297896, g.135863848G>T in 
GRCh37/hg19) (Figure 1B: 1) that was associated with abnormal 
function and reduced platelets in an individual of Asian Indian 
ancestry; however, the variant was not found in 321 Indian Asian 
genomes (25).
Whole-exome sequence in 15,459 unselected individuals 
revealed a synonymous GFI1B variant—Phe192 (c.576C>T, 
rs150813342, g.135864513C>T in GRCh37/hg19, MAF = 0.009) 
(Figure  1B: 2)—that was associated with low platelet count. 
Heterozygous carriers had an average platelet reduction of 
25–30 ×  109/L. This change promotes the short splicing form, 
affecting megakaryocyte differentiation and platelets, but not red 
cell production (26).
All these mutations demonstrate the fundamental role of 
GFI1B in the biogenesis of human platelets.
GFi1B AnD MALiGnAnCY
Mutations that block differentiation and those that promote 
cell survival or proliferation have been considered necessary 
for developing acute leukemia (48). Therefore, the major role of 
GFI1B in hematopoiesis makes it a good candidate to be involved 
in blood cancers (49). Besides its role in cell differentiation, 
GFI1B has been reported to possess proapoptotic activity when 
expressed in human CD34+ cells (50); disruption of this function 
may also contribute to leukemogenesis.
In keeping with this, GFI1B expression has been found in high 
levels in some primary CD34+ human acute myeloid leukemias 
(AMLs) and leukemic cell lines. GFI1B silencing in these cell lines 
decreased proliferation and increased apoptosis (51). In chronic 
myeloid leukemia (CML), other myeloproliferative neoplasms 
(MPNs), AML, and B-lymphoblastic leukemias, GFI1B expres-
sion has also been observed to increase. Remarkably, the short 
GFI1B isoform is highly expressed in the leukemic cells. However, 
both isoforms were higher in CML after treating with tyrosine 
kinase inhibitors (52). Simultaneous silencing of BCR-ABL1 and 
GFI1B in CML cells showed a cooperative antiproliferative and 
proapoptotic effect in the K562 CML cell line (53). In this context, 
the short form may be acting as a repressor over the long species. 
The caveat of these experiments is the low number of patients and 
controls analyzed.
JAK2 V617F mutation is frequent in MPNs but has also been 
found in the general population (0.14–0.2%). Consistent with the 
importance of the GFI1B downstream sequence in its regulation 
and the role of this gene in blood cancer, a genome-wide associa-
tion study identified a C>G variation in this region (rs621940, 
g.135870130C>G in GRCh37/hg19), which is associated with 
MPN patients and normal carriers of JAK2 V617F, but not with 
normal unmutated individuals (p = 1.9 × 10−7) (54). Similarly, 
we reported GFI1B promoter mutations in human leukemias. 
However, no clear link has yet been established between these 
mutations and hematopoietic neoplasms (55).
Gfi1b repression of oncogene Meis1 also suggests that 
GFI1B is involved in leukemia when its repressor function is 
abolished (7).
In light of these evidences, we described a dominant-negative 
GFI1B mutation, Asp262Asn (c.784G>A, g. 135865264G>A 
in GRCh37/hg19) (Figure 1B: 3), associated with transition to 
AML from antecedent myelodysplastic syndrome (MDS). This 
mutation promotes the survival of normal and MDS human bone 
marrow CD34+ cells and skews lineage output of these normal 
adult primary cells and human cord blood common myeloid 
progenitors toward myeloid cells. This mutant works mainly 
through master hematopoietic regulator SPI1 (PU.1) (34). In 
agreement with this, SPI1 is upregulated in JAK2 V617F-positive 
MPNs (56).
Similar to GFI1 (57, 58), GFI1B has been linked to lymphom-
agenesis. TF TCF3 (E2A) is involved in T-cell human leukemias, 
and Tcf3 KO develops T-cell lymphoma. Ectopic expression of 
Tcf3 in this context induces growth arrest and apoptosis, together 
with direct Gfi1b upregulation. Gfi1b-increased expression in 
Tcf3−/− cells produces similar consequences. Therefore, consist-
ent with the importance of GFI1B block in myeloid leukemias, 
TCF3 inhibition in T-cell malignancies may work through GFI1B 
downregulation (33). Another piece of evidence of the implica-
tion of GFI1B reduction in lymphoma comes from its relation 
with B-cell lymphoma 6 (BCL6), a gene frequently expressed in 
T- and B-cell lymphomas. BCL6 chromosomal rearrangements 
and/or mutations are associated with human lymphomas, up 
to 73% in diffuse large B-cell lymphoma (59). Gfi1b has been 
identified as a retrovirus integration site in diffuse large B-cell 
lymphomas of mice containing the human BCL6 transgene, 
but this was not the case in retroviral injected non-transgenic 
control lymphomas. Again, in this context, Gfi1b expression 
was decreased in the first lymphomas compared with the latest. 
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Additionally, GFI1B was decreased in human BCL6-positive T- 
and B-cell lymphomas, analyzed by immunohistochemistry (60).
Unlike blood malignancies, GFI1B and GFI1 activation has 
been associated with solid tumors, in particular medulloblas-
toma. In most cases, GFI1B/GFI1 mutually exclusive abnormal 
expression was produced by structural variants, showing that 
abnormal expression of GFI1B is definitely linked with human 
cancer (61–63). Further investigation may establish a wider role 
in blood or solid malignancy.
Other genes have been related to malignancy both when 
upregulated and functionally inactivated, including key regula-
tors of hematopoiesis CEBPA (64) and SPI1 (PU.1) (56, 65, 66). 
This may be the case with GFI1B too. However, more data will 
be needed to get a full insight into the mechanisms involved in 
GFI1B’s role in cancer, particularly in the blood setting and the 
importance of its two isoforms.
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